Pharmaceutical industry is boon to any country for its commitment towards alleviation of chronic/non-chronic disease by new chemical entity or generics. To facilitate this objective, an organization faces many IP and technology challenges for bringing new innovative drug in market or launching generics at reasonable prices to mass.
Providing solutions for IP and technology challenges pertaining at any stage of R&D/launch of novel molecules and generics does require very extensive knowledge of the subject matter apart from expertise in executing various IP & technology intelligence projects. IEBS pharma team fits exactly in this context. The team comprises of people having an impeccable blend of subject knowledge, industry R&D and IP experience.
IEBS pharma team has provided innovative IP and technology solutions to pharmaceutical companies worldwide in various domains – small molecules, biotherapeutics, biosimilars, therapies for rare diseases, secondary indications etc.
Subject Matter Expertise
Significant Breadth and Depth Experience Across the Pharmaceuticals Domain
Technology Drug formulation with increased bioavailability for dosage reduction
Technology Landscape PEG-conjugated small molecules
Innovation Small molecule drug targets in cancer
Technology Intelligence Solid phase peptide synthesis in therapeutics
White Space Analysis Epigenetics in cancer therapeutics
Technology Landscape Antibody Drug conjugate in cancer therapeutics
Patent Landscape on Stem cell cellular disease models
Freedom on Small molecule metabolite as glucose biosensor
Freedom on Microbubble DNA and RNA Delivery Technology
Patentability on Humanized TTR Mice
Prior on Octreolide Delivery
Patent Landscape on Epidermal growth factor receptor (EGFR) kinase inhibitors in cancer therapeutics
Market Assessment on Organic Excipients
Competitive Intelligence on Oral mouth rinse for kids
Business Opportunities Non invasive drug delivery system
Market size Monoclonal Antibodies
Market Opportunity Assesment Existing and Potential market of Crispr/cas9